Retatrutide Research Vial 30 mg
Catalogued in the papers as LY3437943. What ships is a freeze-dried cake sealed in a 3 ml glass vial, 30 mg of material in total. Dissolve it in an equal 3 ml of bacteriostatic water and you land on a nominal 10 mg per ml. Stock is held back from sale until an outside laboratory has signed off on identity and purity.
Handling in three steps
Reconstitution decides whether a series stays comparable. Nothing here is dosing guidance.
-
01
Let it come up to room temperature
Twenty to thirty minutes on the bench, until the glass no longer feels cold. Then swab the septum with alcohol and wait for it to dry.
-
02
Aim at the glass, not the cake
Let 3 ml of bacteriostatic water run down the inner wall under low pressure. The cake will clear on its own; rotation helps, agitation does not.
-
03
Date the label, then refrigerate
Note the volume you actually added, since 10 mg/ml assumes the full 3 ml went in. An undated vial is an unusable vial two weeks later.
What is in the box
| Compound | Retatrutide (LY3437943) |
| Presentation | Lyophilised cake, 3 ml vial |
| Quantity | 30 mg total |
| After reconstitution | 10 mg/ml with 3 ml solvent |
| Purity | ≥ 99% (HPLC) |
| Solvent | Bacteriostatic water, sold separately |
| Storage | Refrigerated, protected from light |
| Origin | European Union, ISO-certified facility |
| Intended use | Laboratory research only |
Made and checked in Europe
Both the chemistry and the filling happen inside the EU, at an ISO-certified site. People tend to focus on the synthesis, but for a freeze-dried product the drying stage decides just as much: what sits in the vial has to be properly dry, evenly formed and clear of leftover solvent by the time the stopper is seated.
When a run closes, samples go out to a laboratory with no stake in the result. The release threshold is 99% by HPLC; anything under that never reaches the catalogue. Because the run is identified on the carton, the box in front of you maps onto one specific set of analytical results rather than a general claim about our stock.
As for the molecule: LY3437943 is a synthetic sequence built so that one backbone can act at the GLP-1, GIP and glucagon receptors together. Papers refer to this as a triple agonist in a single molecule — a design that lets researchers compare receptor combinations inside one construct instead of stacking several separate substances. The sequence also carries a lipid side chain, a modification the pharmacokinetic work links to albumin binding.
The bulk of what has been published lives in binding assays, cell signalling models and animal work. None of that is a statement about people. This material has been characterised for one context only: a controlled laboratory. More on the route itself in the GLP-1 pathway.
Read up on this one first
Four pages that explain what this molecule is, how it sits against the better-known GLP-1 compounds, and what the trial protocols actually recorded.
About this vial
The questions researchers put to us most often about this particular item.
Why is it supplied dry instead of in solution?
How much material does one vial contain?
How should it be stored, before and after reconstitution?
Where is this material produced?
Can I see the certificate for my batch?
How quickly does an order ship?
What is this sold for?
Purity you can check on paper
Every batch is analysed by a laboratory with no stake in the result, and the certificate is yours on request. Ask for the batch number before you order, not after.
For laboratory and research use only. Not for human or animal consumption. Not a medicine and not a food supplement. Sold to persons aged 18 and over.